Acid suppressant therapy's chronic disease anchor — the proton pump inhibitors (PPIs), H2 receptor antagonists, and emerging potassium-competitive acid blockers (P-CABs) used to manage gastroesophageal reflux disease, peptic ulcer disease, and related acid-related gastrointestinal disorders — represents one of the largest and most consistently utilized therapeutic categories in...